Posted by Michael Wonder on 31 Jul 2021
Increased manufacturing capacity and supply for Spikevax
30 July 2021 - EMA's CHMP has approved a scale-up of the active substance production process at Moderna's COVID-19 vaccine manufacturing sites in the United States.
This recommendation is expected to have significant impact on the supply of Spikevax, the COVID-19 vaccine developed by Moderna, in the European Union.
